Navigation Links
Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
Date:11/20/2007

CRANBURY, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the Lazard Capital Markets Fourth Annual Healthcare Conference in New York City on Tuesday, November 27th at 11:30 am ET at The New York Palace Hotel.

A live audio web cast of the presentation will be available to all interested parties through the Investors section of Amicus' website at http://www.amicustherapeutics.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has two product candidates in Phase II clinical trials, Amigal(TM) for the treatment of Fabry disease and Plicera(TM) for the treatment of Gaucher disease. The Company announced positive data from Phase I clinical trials of AT2220 for the treatment of Pompe disease in October 2007.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forw
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 WriteResult, a premier provider ... from Yale University’s School of Public Health and New ... during a 4 month-long project. The goal of the ... income families with free access to fresh produce and ... health concerns like high blood pressure, diabetes and weight ...
(Date:3/25/2015)... Agnition announced today that it will be featured ... the first time at 7:30 a.m. CST March 31 ... the extremely important role soil microbes perform in crop ... Catalyst™ technology that enhances soil and plant health for ... again on April 28. , A biochemist at Agnition ...
(Date:3/25/2015)... 25, 2015 Optimal Research, LLC has been ... (ViE) Award "Best Clinical Site or Trial Network". ... has been selected as a nominee in this ViE ... "Highly Recommended" distinction in 2014. The ViE awards were ... accomplishments, and positive contributions of companies and individuals in ...
(Date:3/25/2015)... NEW YORK , March 25, 2015 /PRNewswire/ ... has commenced Factual Stock Report coverage on ... Bioceuticals (OTCQX: ATTBF; CSE: ATT): is a specialty ... subsidiaries of cultivating, licensing and marketing proprietary ingredients, ... medicinal markets in North America ...
Breaking Biology Technology:Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... ... 2, 2009. , ... Portland, Maine (PRWEB) June 26, 2009 -- IntertechPira, in conjunction with the National Hydrogen ... conference bringing together hydrogen producers, developers and users to discuss the future of this ...
... , , , , NORCROSS, Ga., ... in providing automated instrument-reagent systems to the blood transfusion industry, ... an administrative action based on an early January 2009 inspection, ... license with respect to its Reagent Red Blood Cells and ...
... Clavis Pharma ASA (OSE:,CLAVIS) today announced that the Company ... gross proceeds through a private placement,of 10,750,000 new shares, each ... of NOK,12.00 per share (the "Private Placement"). , ... process and was,managed by Carnegie ASA and DnB NOR Markets ...
Cached Biology Technology:Industry Leaders Will Gather to Discuss the Future of the "Hydrogen Economy" in Washington DC 2Immucor Responds To FDA Notice 2Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 2Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 3Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 4Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 5
(Date:3/18/2015)... CORAL SPRINGS, Florida , March 18, 2015 ... as well as businesses, new revolutionary smart wallets and apps ... rapid pace.  Companies currently entrenched in the mobile payment industry ... ), Alibaba Group Holding Ltd. (NYSE: BABA ), ... GOOG ) and Facebook Inc. (NASDAQ: ...
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
(Date:3/12/2015)... 12, 2015 WHEN:Tuesday, March 17, 2015 at ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan Measurement ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must plan ... several different markets and industries. This is especially ... uptrend. Join Frost & Sullivan,s ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... developer and manufacturer of advanced molecular sensing and imaging ... that it has signed exclusive distribution deals for both ... markets covered include Australia, New Zealand, The Netherlands, ... Greece, Turkey, and Russia. The values of the ...
... for U.S. Department of Agriculture,s (USDA) Center for Veterinary Biologics ... each batch of a vaccine, the CVB has informed PETA ... with modern non-animal methods. The USDA has amended its Web ... CVB to follow the lead of Europe in adopting an ...
... newswire / - ERGONEX Pharma received one of the ... occasion of Frost & Sullivan,s ,2009 Excellence in Healthcare ... The highly competitive award was presented to ERGONEX Pharma ... impressive display of technological know-how and targeted vision. , ...
Cached Biology News:Spectros Signs New International Distribution Deals 2ERGONEX Pharma receives Frost & Sullivan's European Orphan Diseases Entrepreneurial Company Award 2009 2
... The dsRNA Marker consists of ten double-stranded ... 300, 400, 500 and 1,000 base pairs. ... marker for determinating sizes of double-stranded RNAs. ... the dsRNA Marker is adjusted to approximately ...
... White to off-white solid. A ... and blocks the formation of N-glycosidic ... against Gram-positive bacteria, yeasts, fungi, ... functional thrombin receptors on human T-lymphoblastoid ...
... enzymes involved in matrix degradation. Of the ... exist in soluble form whereas MT-MMPs exist ... also known as MMP14, MMP15, MMP16 respectively ... to the cell surface. They have an ...
...
Biology Products: